Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Wolfe Research on Compass Pathways (CMPS): 'we expect the stock to regain strong momentum after this pullback'
July 7, 2026 3:52 PM EDTWolfe Research analyst Rudy Li reiterated an Outperform rating and $18.00 price target on Compass Pathways (NASDAQ: CMPS).
The analyst comments "COMP006's durable 26-week data, improved responder/remission rates, and clean safety profile keep the NDA/1H27 launch on track We view today's... More
Oppenheimer on Compass Pathways (CMPS): 'Reinforced Durability Strengthens Launch Prospects'
July 7, 2026 12:11 PM EDTOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $20.00 price target on Compass Pathways (NASDAQ: CMPS).
The analyst comments "We view the Ph3 COMP006 26-week data as reinforcing the durable efficacy profile of COMP360 (psilocybin), representing a transformative approach for the ~4M addressable TRD patients. CMPS previously observed 26-week durability in the Ph3 COMP005 study, and now shows consistent results for this second pivotal study with ~30% of responders achieving remission following re-treatment in the Part-B portion. We... More
Compass Pathways (CMPS) PT Raised to $25 at BTIG, 'executed nearly flawlessly on everything within its control'
July 7, 2026 12:10 PM EDTBTIG analyst Madison El-Saadi raised the price target on Compass Pathways (NASDAQ: CMPS) to $25.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "This was bound to happen if enough patients were treated and today's call disclosed one suspected completed suicide in the 25mg arm, deemed not related to treatment by the investigator based on specific circumstances and timing. All these qualifications suggest the event has already triggered extensive discussion, and we expect the discussion to continue. Suicide is part of the TRD landscape and that unfortunate reality was also driven... More
